James B. Breitmeyer - Feb 14, 2024 Form 4 Insider Report for Oncternal Therapeutics, Inc. (ONCT)

Role
Chief Executive Officer, Director
Signature
/s/Chase C. Leavitt, Attorney-in-fact
Stock symbol
ONCT
Transactions as of
Feb 14, 2024
Transactions value $
$0
Form type
4
Date filed
2/15/2024, 06:00 PM
Previous filing
Jan 5, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ONCT Stock Option Award $0 +28.4K $0.00 28.4K Feb 14, 2024 Common Stock 28.4K $9.18 Direct F1
transaction ONCT Stock Option Award $0 +6.2K $0.00 6.2K Feb 14, 2024 Common Stock 6.2K $9.18 By Spouse F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the stock option vest on first anniversary of the date of grant, and the remaining shares subject to the option vest in 36 equal monthly installments, subject to the recipient's continued employment or service with the Issuer on each such date.